Cargando…
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
The grades of neurosensory adverse events (NSAEs) induced by FOLFOX4 treatment were compared between Asian and Western colorectal cancer patients and correlated with cumulative oxaliplatin doses. A total of 3359 patients treated with FOLFOX4 were analyzed: 1515 from two Asian studies (Japanese Post...
Autores principales: | Sugihara, Kenichi, Ohtsu, Atsushi, Shimada, Yasuhiro, Mizunuma, Nobuyuki, Gomi, Katsushige, Lee, Po-Huang, Gramont, Aimery, Rothenberg, Mace L, André, Thierry, Brienza, Silvano, Goldberg, Richard M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544454/ https://www.ncbi.nlm.nih.gov/pubmed/23342269 http://dx.doi.org/10.1002/cam4.25 |
Ejemplares similares
-
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
por: Hamidou, Zeinab, et al.
Publicado: (2016) -
mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival
por: Yasuno, Masamichi, et al.
Publicado: (2019) -
New curative approach using embolization followed by moderate-dose radiotherapy after surgical failure for large right heart metastasis
por: Delanian, Sylvie, et al.
Publicado: (2021) -
Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015) -
Fisiología neurosensorial en otorrinolaringología
Publicado: (1985)